drugset / Trial / NCT02581826

Safety and Efficacy of Silodosin in the Treatment of Premature Ejaculation

NCT02581826

RandomizedCrossoverQuadruple-blindTreatment

Summary

The objectives of the present study aims to evaluate the safety and efficacy of Silodosin in a population of patients wih Premature Ejaculation (PE). Coupled with efficient diagnosis, it is hoped that the newer agent will improve the quality of life for patients who suffer from Premature Ejaculation (PE).

Timeline

Start
2013-10
Primary completion
2016-12
Completion
2016-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Silodosin Unknown 4 mg Oral

Indications